Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring exenatide, exendin-4, diabetes, Amylin, Lilly
Eligibility Criteria
Main Inclusion Criteria: Treated with a stable dose of metformin or sulfonylurea for at least 3 months prior to screening. HbA1c between 7.1% and 11.0%, inclusive. Insulin therapy should be the next appropriate step of diabetes treatment. Body Mass Index (BMI) >25 kg/m2 and <40 kg/m2. Main Exclusion Criteria: Patient previously in a study involving exenatide or glucagon-like peptide-1 analogs. Treated with insulin, thiazolidinediones, alpha-glucosidase inhibitors, or meglitinides within 3 months prior to screening.
Sites / Locations
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
- Research Site
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
exenatide/insulin glargine
Insulin glargine/exenatide
Arm that first receives exenatide, then crosses over to insulin glargine
Arm that first receives insulin glargine, then crosses over to exenatide